Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dexter

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Journal of Neurochemistry|August 24, 2007
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivoAnthony C Vernon, Virginia Zbarsky, Krishna P Datla, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 3, 2006
Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivoAnthony C Vernon, Virginia Zbarsky, Krishna P Datla, et al.
Journal of Molecular Neuroscience : MN|May 19, 2015
Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's DiseaseMichael J Hurley, Pascal F Durrenberger, Steve M Gentleman, et al.
Journal of Neuroinflammation|June 7, 2005
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein depositionEmilie Croisier, Linda B Moran, David T Dexter, et al.
Neuroreport|January 25, 2003
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycleKrishna P Datla, Hilary E Murray, Arani V Pillai, et al.
Journal of Neurochemistry|June 25, 2009
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's diseaseLilia Marinova-Mutafchieva, Mona Sadeghian, Lauren Broom, et al.
Free Radical Research|November 22, 2005
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's diseaseVirginia Zbarsky, Krishna P Datla, Shabnam Parkar, et al.
Free Radical Biology & Medicine|December 28, 2010
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson diseaseLauren Broom, Lilia Marinova-Mutafchieva, Mona Sadeghian, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 20, 2020
Iron and inflammation: in vivo and post-mortem studies in Parkinson's diseaseAntonio Martin-Bastida, Bension Shlomo Tilley, Sukhi Bansal, et al.
Journal of the American College of Nutrition|October 2, 2007
Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's diseaseKrishna P Datla, Virginia Zbarsky, Deepal Rai, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Journal of Neurochemistry|August 24, 2007
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivoAnthony C Vernon, Virginia Zbarsky, Krishna P Datla, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 3, 2006
Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivoAnthony C Vernon, Virginia Zbarsky, Krishna P Datla, et al.
Journal of Molecular Neuroscience : MN|May 19, 2015
Altered Expression of Brain Proteinase-Activated Receptor-2, Trypsin-2 and Serpin Proteinase Inhibitors in Parkinson's DiseaseMichael J Hurley, Pascal F Durrenberger, Steve M Gentleman, et al.
Journal of Neuroinflammation|June 7, 2005
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein depositionEmilie Croisier, Linda B Moran, David T Dexter, et al.
Neuroreport|January 25, 2003
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycleKrishna P Datla, Hilary E Murray, Arani V Pillai, et al.
Journal of Neurochemistry|June 25, 2009
Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's diseaseLilia Marinova-Mutafchieva, Mona Sadeghian, Lauren Broom, et al.
Free Radical Research|November 22, 2005
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's diseaseVirginia Zbarsky, Krishna P Datla, Shabnam Parkar, et al.
Free Radical Biology & Medicine|December 28, 2010
Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson diseaseLauren Broom, Lilia Marinova-Mutafchieva, Mona Sadeghian, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 20, 2020
Iron and inflammation: in vivo and post-mortem studies in Parkinson's diseaseAntonio Martin-Bastida, Bension Shlomo Tilley, Sukhi Bansal, et al.
Journal of the American College of Nutrition|October 2, 2007
Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's diseaseKrishna P Datla, Virginia Zbarsky, Deepal Rai, et al.
Pageof 7